Our data thus suggests ontogenic differences in the sensitivity of MLL::ENL-driven leukemia to inhibition of pathways under the control of Mthfd2 and Mtap, highlighting potential opportunities for age-tailored therapeutic approaches. This evidence concerns the gene MTAP and leukemia.